Phase I Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients With Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma
Summary
The purpose of this phase 1 multi-center, open-label, first in human study of the safety, tolerability, feasibility, and preliminary efficacy of the administration of genetically modified autologous T cells (CART-TnMUC1 cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen, TnMUC1 and activating the T cell (CART- TnMUC1 cells).
General Information
NCT#: NCT04025216
Study ID: CART-TnMUC1-01
Trial Phase: Phase I
Trial Sponsor: Tmunity Therapeutics
Therapies Used in This Trial: Cyclophosphamide, Fludarabine, CART-TnMUC1